← Eichor
Condition: Refractory Multiple Myeloma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Refractory Multiple Myeloma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109323Limited-duration Teclistamab
Phase 2 · 5 location(s) · Abramson Cancer Center at Penn Medicine · NCT05932680A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants
Phase 2 · 51 location(s) · GlaxoSmithKline · NCT07227311A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Phase 1/Phase 2 · 11 location(s) · IDP Discovery Pharma S.L. · NCT05908409Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/Phase 2 · 24 location(s) · Heidelberg Pharma AG · NCT04879043AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Phase 1/Phase 2 · 36 location(s) · AstraZeneca · NCT05850234LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
NA · 4 location(s) · Nanjing Legend Biotech Co. · NCT07100067A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With
Phase 3 · 109 location(s) · Janssen Research & Development, LLC · NCT07258511A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Ref
Phase 1 · 5 location(s) · Hoffmann-La Roche · NCT06934044A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/Phase 2 · 26 location(s) · Nanjing Leads Biolabs Co.,Ltd · NCT06049290A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light
Phase 1 · 29 location(s) · Janssen Research & Development, LLC · NCT05652335Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
NA · 1 location(s) · University Health Network, Toronto · NCT06485076Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refrac
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07181941Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 · 1 location(s) · Benjamin T Diamond, MD · NCT05896228CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitor
Phase 1 · 1 location(s) · Peter MacCallum Cancer Centre, Australia · NCT05666700Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Phase 1/Phase 2 · 1 location(s) · Xuzhou Medical University · NCT06196255A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
EARLY_Phase 1 · 4 location(s) · Suzhou Immunofoco Biotechnology Co., Ltd · NCT074931353'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT06920251Elranatamab in Relapsed/Refractory Multiple Myeloma
Phase 2 · 1 location(s) · University of California, San Diego · NCT06711705Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
NA · 1 location(s) · Anhui Provincial Hospital · NCT06961669Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06581640A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07454382Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Phase 2 · 2 location(s) · Hrain Biotechnology Co., Ltd. · NCT05594797A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
EARLY_Phase 1 · 5 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07294625Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Phase N/A · 1 location(s) · Sung-Soo Park · NCT07051850
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.